Connect with us

Hi, what are you looking for?

Friday, Mar 24, 2023
Mugglehead Magazine
Alternative investment news based in Vancouver, B.C.


Woke Pharma and Swinburne U partner for Australia’s biggest psilocybin trial

The AUD$5M study will involve about 160 participants and aims to help combat treatment-resistant depression

Woke Pharma and Swinburne U partner for Australia's 'biggest' psilocybin trial
Psilocybin mushrooms. Photo via Swinburne University of Technology, Melbourne, Australia

An Australian psychedelic therapy company has partnered with a university in Melbourne for a large-scale clinical trial on psilocybin with the goal of combatting treatment-resistant depression.

On Monday, Swinburne University of Technology announced that it had signed a AUD$5 million clinical trial agreement with Sydney’s Woke Pharmaceuticals.

The psilocybin drug candidate for the study, designated as WP002, is a rapid-release tablet developed by Woke Pharma. Enrolment for the trial is expected to begin mid-way through this year and the two parties involved expect that there will be approximately 160 participants.

Read more: Mind Medicine Australia receives AUD$1M grant for psychedelic research

Read more: Apex Labs doses first patient in Veterans take-home psilocybin drug trial

According to Woke and Swinburne, this is the largest clinical trial on psilocybin in Australia’s history.

“I am excited to be leading this trial. We have the opportunity to make a substantial difference and for Australia to lead the way in psychedelics research,” said Lead Researcher, Professor Susan Rossell.

“Psychedelics could transform the landscape of treatments for many psychiatric disorders, including major depression,” she added.

Rossell is a cognitive neuropsychologist at Swinburne’s Centre for Mental Health.

Woke Pharmaceuticals‘ Director and CEO Nick Woolf also conveyed his enthusiasm for the upcoming study.

“This trial will inform the further development and potential registration of WP002 psilocybin-assisted psychotherapy as an effective treatment approach for patients living with this debilitating condition,” said Woolf.

“In addition, the trial will investigate the potential economic benefits to the healthcare system and society from durable remission of depression.”

Read more: Biomind Labs develops sublingual psychedelic drug to treat Alzheimer’s

Read more: Non-profit launches supporting psychedelic traditions of Mexico’s Indigenous peoples

Australia has been a significant contributor to psychedelic research in recent years

Last August for example, Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) began clinical trials in the country on two of its psilocin analogues (active ingredient in psilocybin) and the Australian government was able to provide the company with a 43.5 per cent rebate on expenditures related to the study through its Research and Development Tax Incentive program.

Earlier last year in January a team of scientists at the University of Sydney received approximately $2.8 million in government funding to study MDMA for the treatment of post-traumatic stress disorder (PTSD) and alcohol use disorder.

In 2021, Australia’s Medical Research Future Fund organized a $14.5 million grant for psychedelic research and clinical trials.


Follow Mugglehead on Twitter

Like Mugglehead on Facebook

Follow Rowan Dunne on Twitter




Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like


The deposit is situated in China's eastern Shandong province and state media says it will produce 50 tonnes of gold


'SANA-013' is a proprietary therapy intended to treat conditions like migraines, episodic cluster headaches and MDD


The state's House of Representatives approved the legislation on Thursday


The company will supply Mind Medicine Australia with the substances, now considered designated therapies in the country